An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pfizer's Depo-Provera shot has been linked to brain tumors — and hundreds of women are suing the pharmaceutical giant over it ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...